Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effectiveness of Prescription-Based CNS Stimulants on Hospitalization in Patients With Schizophrenia: A Nation-Wide Register Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Association Between Childhood Green Space, Genetic Liability, and the Incidence of Schizophrenia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Emotion Recognition and Adverse Childhood Experiences in Individuals at Clinical High Risk of Psychosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Electrocardiogram Characteristics and Their Association With Psychotropic Drugs Among Patients With Schizophrenia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Identifying Schizo-Obsessive Comorbidity by Tract-Based Spatial Statistics and Probabilistic Tractography

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Electrocardiogram Characteristics and Their Association With Psychotropic Drugs Among Patients With Schizophrenia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. One-Year Follow-up on Liraglutide Treatment for Prediabetes and Overweight/Obesity in Clozapine- or Olanzapine-Treated Patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Complex spatio-temporal distribution and genomic ancestry of mitochondrial DNA haplogroups in 24,216 Danes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Real-World Effectiveness of Clozapine for Borderline Personality Disorder: Results From a 2-Year Mirror-Image Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: Negative symptoms and cognitive deficits are main features of schizophrenia but with limited treatment options. Earlier studies have suggested that central nervous system (CNS) stimulants have a small effect on these domains, but with inconclusive results. As the first study to date, we aimed to investigate whether CNS stimulants improve naturalistic outcomes (psychiatric admissions and antipsychotic use) in patients with schizophrenia.

METHODS: By using extensive health registers all patients with schizophrenia and their use of CNS stimulants in Denmark were identified. Two models were used to investigate the effectiveness of CNS stimulants in patients with schizophrenia between 1995 and 2014; a mirror-image model with 605 individuals, using paired t tests and Wilcoxon signed rank tests, and a follow-up study with 789 individuals, using a conditional risk-set model.

RESULTS: CNS stimulants use was associated with a reduction in number of psychiatric admissions from 3.43 (95% CI = 2.86 to 4.01) to 2.62 (95% CI = 1.99 to 3.25) (P = .009), with a more pronounced reduction for women (mean difference: -1.37, 95% CI = -2.34 to -0.40, P = .006). Psychiatric bed-days were reduced by 40 (95% CI = 24.5 to 55.6, P < .001) for individuals with at least 1 admission before CNS stimulant use. In addition, the total amount of antipsychotic use (Defined Daily Dose [DDD]) was reduced (P = .001). The Hazard rate ratio in psychiatric admissions between women taking CNS stimulants compared to women not taking CNS stimulants was 0.77 (95% CI = 0.67 to 0.88).

CONCLUSION: CNS stimulants may have clinical potentials for improving functional outcomes in patients with schizophrenia and randomized clinical studies evaluating this topic are warranted.

OriginalsprogEngelsk
TidsskriftSchizophrenia Bulletin
Vol/bind44
Udgave nummer1
Sider (fra-til)93-100
Antal sider8
ISSN0586-7614
DOI
StatusUdgivet - 13 jan. 2018

ID: 52704608